Bendamustine 180 Mg/4 Ml Drl 180 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 21 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
First-line treatment for specific leukemias and lymphomas.
Dosage (summary)
100 mg/mu00b2 on days 1 and 2 for CLL; 90 mg/mu00b2 for NHL with rituximab; 120-150 mg/mu00b2 for multiple myeloma.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP1A2 inhibitors
- Myelosuppressive agents
- Ciclosporin
- Tacrolimus
Contraindications
- Hypersensitivity
- Severe hepatic impairment
- Severe bone marrow suppression
- Pregnancy
- Lactation
Common side effects
- Leucopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Rash
Counselling Points
- Monitor for signs of infection
- Avoid pregnancy
- Consider PJP prophylaxis if CD4 < 200
- Report severe skin reactions immediately
Serious warnings
- Myelosuppression
- Infections
- Hepatitis B reactivation
- Skin reactions
- Anaphylaxis
On This Page
Connecting to Document Server
Decrypting and optimizing pharmaceutical leaflet...
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
